These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 22445288)
1. The three main stumbling blocks for anticancer T cells. Baitsch L; Fuertes-Marraco SA; Legat A; Meyer C; Speiser DE Trends Immunol; 2012 Jul; 33(7):364-72. PubMed ID: 22445288 [TBL] [Abstract][Full Text] [Related]
2. Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer. Ramanathan S; Gagnon J; Ilangumaran S Arch Immunol Ther Exp (Warsz); 2008; 56(5):311-23. PubMed ID: 18836862 [TBL] [Abstract][Full Text] [Related]
3. Cellular therapy to control tumor progression. Kapp M; Rasche L; Einsele H; Grigoleit GU Curr Opin Hematol; 2009 Nov; 16(6):437-43. PubMed ID: 19587587 [TBL] [Abstract][Full Text] [Related]
4. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Peggs KS; Quezada SA; Allison JP Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925 [TBL] [Abstract][Full Text] [Related]
5. [Regulation of T-cell immune exhaustion and cancer immunotherapy]. Eikawa S; Udono H Gan To Kagaku Ryoho; 2014 Sep; 41(9):1066-70. PubMed ID: 25248889 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929 [TBL] [Abstract][Full Text] [Related]
7. Considerations on clinical use of T cell immunotherapy for cancer. Plautz GE; Cohen PA; Shu S Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434 [TBL] [Abstract][Full Text] [Related]
8. Targeting the stroma by T cells to limit tumor growth. Zhang B Cancer Res; 2008 Dec; 68(23):9570-3. PubMed ID: 19047130 [TBL] [Abstract][Full Text] [Related]
9. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606 [TBL] [Abstract][Full Text] [Related]
11. Immunity and metastasis: in situ activation of protective T cells by virus modified cancer vaccines. Schirrmacher V Cancer Surv; 1992; 13():129-54. PubMed ID: 1423321 [TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Berry LJ; Moeller M; Darcy PK Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368 [TBL] [Abstract][Full Text] [Related]
14. Making and circumventing tolerance to cancer. Kammertoens T; Blankenstein T Eur J Immunol; 2009 Sep; 39(9):2345-53. PubMed ID: 19634191 [TBL] [Abstract][Full Text] [Related]
15. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Zhang B; Zhang Y; Bowerman NA; Schietinger A; Fu YX; Kranz DM; Rowley DA; Schreiber H Cancer Res; 2008 Mar; 68(5):1563-71. PubMed ID: 18316622 [TBL] [Abstract][Full Text] [Related]
16. Interleukin 15 as a promising candidate for tumor immunotherapy. Jakobisiak M; Golab J; Lasek W Cytokine Growth Factor Rev; 2011 Apr; 22(2):99-108. PubMed ID: 21531164 [TBL] [Abstract][Full Text] [Related]
17. 4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members. Kroon HM; Li Q; Teitz-Tennenbaum S; Whitfield JR; Noone AM; Chang AE J Immunother; 2007; 30(4):406-16. PubMed ID: 17457215 [TBL] [Abstract][Full Text] [Related]
19. The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Abastado JP Cancer Res; 2012 May; 72(9):2159-61. PubMed ID: 22549945 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy: target the stroma to hit the tumor. Kammertoens T; Schüler T; Blankenstein T Trends Mol Med; 2005 May; 11(5):225-31. PubMed ID: 15882610 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]